Stock EFTR EFFECTOR THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Sector Chart eFFECTOR Therapeutics, Inc.

Equities

EFTR

US28202V2079

Delayed Nasdaq
Other stock markets
 01:00:16 2024-06-03 pm EDT 		5-day change 1st Jan Change
1.59 USD -0.62% Intraday chart for eFFECTOR Therapeutics, Inc. -9.14% -86.39%
May. 20 EFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer CI
May. 09 EFFECTOR Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes

Sector Bio Therapeutic Drugs

Capi. Sales growth Profitability Finances EV / Sales P/E ratio
EFFECTOR THERAPEUTICS, INC. Stock eFFECTOR Therapeutics, Inc.
 7.53M - - - - -
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
 118B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
 106B
BIONTECH SE Stock BioNTech SE
 24.28B -
ARGENX SE Stock argenx SE
 21.96B -
GENMAB A/S Stock Genmab A/S
 18.16B
  1. Stock Market
  2. Equities
  3. EFTR Stock
  4. Charts eFFECTOR Therapeutics, Inc.
  5. Sector Chart